For most of 2012 and 2013, Covidien (NYSE:COV) was the not-so-little med-tech that could. In an environment were companies like Johnson & Johnson (NYSE:JNJ), Bard (NYSE:BCR), Stryker (NYSE:SYK), and Abbott (NYSE:ABT)
were struggling to deliver sustained attractive growth in devices,
Coviden managed to do so. Now, though, it looks like the Street has
caught up with Covidien's prospects and the sequential deceleration in
device growth could make it harder for these shares to outperform.
Still, as one of the best companies in a still-popular sector, I
wouldn't be in a hurry to sell if I owned shares.
Please follow this link for more:
http://www.investopedia.com/stock-analysis/080113/street-has-caught-covidien-cov-jnj-isrg-masi-abt.aspx
No comments:
Post a Comment